GCP
RANI icon

GSA Capital Partners’s Rani Therapeutics RANI Stock Holding History

GSA Capital Partners’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$190K Buy
249,716
+152,718
+157% +$135K 0.01% 1538
2026
Q1 		$71K Buy
+96,998
New +$124K ﹤0.01% 1590
2025
Q3 		– Sell
-25,391
Closed -$13K – 2018
2025
Q2 		$13K Sell
25,391
-19,242
-43% -$15.7K ﹤0.01% 1694
2025
Q1 		$56K Buy
+44,633
New +$66K 0.01% 1541

Other funds holding RANI

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LP
Longaeva Partners Chicago, Illinois $4.58B AUM 43.91% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

GSA Capital Partners's RANI Position: Q2 2026 in Review

GSA Capital Partners increased its Rani Therapeutics (RANI) stake by 157% in Q2 2026, buying an estimated $135K and bringing the position to 249,716 shares worth $190K. The position accounts for 0.01% of the portfolio, ranked #1538.

GSA Capital Partners first reported a position in RANI in Q1 2025 and has held it in 4 quarters since. 68 funds tracked by Wall St. Rank hold RANI as of Q2 2026.

  • GSA Capital Partners held 249,716 shares of Rani Therapeutics worth $190K as of Q2 2026.
  • GSA Capital Partners bought 152,718 Rani Therapeutics shares in Q2 2026, an estimated $135K.
  • Rani Therapeutics made up 0.01% of GSA Capital Partners's portfolio in Q2 2026, its #1538 holding.
  • GSA Capital Partners first reported a position in Rani Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • 68 funds tracked by Wall St. Rank held Rani Therapeutics as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.